Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer

BACKGROUND: Epidermal growth factor receptor-mutated (EGFR(+)) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but implementation is challenging. METHODS: EGFR(+) NSCLC patients treated with first/second-generation (...

Descripción completa

Detalles Bibliográficos
Autores principales: Magios, Nikolaus, Bozorgmehr, Farastuk, Volckmar, Anna-Lena, Kazdal, Daniel, Kirchner, Martina, Herth, Felix J., Heussel, Claus-Peter, Eichhorn, Florian, Meister, Michael, Muley, Thomas, Elshafie, Rami A., Fischer, Jürgen R., Faehling, Martin, Kriegsmann, Mark, Schirmacher, Peter, Bischoff, Helge, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366107/
https://www.ncbi.nlm.nih.gov/pubmed/34408792
http://dx.doi.org/10.1177/1758835921996509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366107/
https://www.ncbi.nlm.nih.gov/pubmed/34408792
http://dx.doi.org/10.1177/1758835921996509

Ejemplares similares